ABOUT US

EKF Diagnostics Holdings plc specialises in the development, production and distribution of near patient analysers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases.

The EKF range of analysers is unique in their ease of use, accuracy and portability which is why we are a trusted brand in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c.

EKF Diagnostics products' reputation for quality, accuracy and ease of use stems from our beginnings as a technology business founded in Barleben in Germany in 1990. In the following years we have invested in developing a portfolio of analysers and consumables for the near patient care sector that deliver laboratory accuracy and reliability without the high costs and maintenance associated with lab devices.

In 2010 EKF Diagnostics acquired HbA1c developer Quotient Diagnostics based in Walton-on-Thames, UK and Argutus Medical in Dublin, a specialist research and distribution company engaged in kidney and liver diagnostics. The following year the company expanded further through the acquisition of Stanbio Laboratory, a manufacturer and distrubutor of diagnostic products with a worldwide customer base.

Today EKF Diagnostics has distributors in more than 70 locations around the globe, multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK and a board led by some of foremost authorities in medical diagnostics in the world.

The ordinary shares of EKF Diagnostics Holdings plc are traded on the AIM market of the London Stock Exchange plc. Details of EKF Diagnostics Holdings plc annual results and financial information can be found in the Investor Relations section of this website.